XOMA Corporation Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Cover
- Document and Entity Information
Financial Statements
Notes to Financial Statements
Accounting Policies
- Basis of Presentation and Significant Accounting Policies (Policies)
Notes Tables
Notes Details

Royalty and Commercial Payment Purchase Agreements - Agenus (Details)

v3.24.3

Royalty and Commercial Payment Purchase Agreements - Agenus (Details) $ in Thousands		1 Months Ended	3 Months Ended	9 Months Ended
	Sep. 20, 2018 USD ($) product	Nov. 30, 2020 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Dec. 31, 2023 USD ($)
Agreements
Payments of consideration under RPAs, AAAs and CPPAs				$ 37,000	$ 14,650
Short-term royalty and commercial payment receivables			$ 12,682	12,682		$ 14,215
Royalty purchase agreement asset impairment			14,000	23,000	$ 1,575
Royalty Purchase Agreement \| Merck Immuno-Oncology Product \| Agenus
Agreements
Amount of milestone payments earned under agreement		$ 10,000
Agenus \| Royalty Purchase Agreement
Agreements
Payments of consideration under RPAs, AAAs and CPPAs	$ 15,000
Acquisition of royalty and commercial payment receivables, Long-Term	$ 15,000
Royalty purchase agreement asset impairment			14,000
Allowance for credit losses			$ 14,000	$ 14,000		$ 0
Agenus \| Royalty Purchase Agreement \| Incyte Immuno-Oncology Assets
Agreements
Royalties entity has right to receive (as a percent)	33.00%
Number of licensed products related to milestone and royalties \| product	6
Milestone payments entity has right to receive (as a percent)	10.00%
Agenus \| Royalty Purchase Agreement \| Merck Immuno-Oncology Product
Agreements
Royalties entity has right to receive (as a percent)	33.00%
Milestone payments entity has right to receive (as a percent)	10.00%
Purchased eligible milestone payments receivable upon achievement of potential development, regulatory and commercial milestones	$ 59,500
Amount of milestone payments earned under agreement		1,000
Reduction in long-term royalty receivable balance due to receipt of payment		$ 1,000

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of allowance for credit loss for right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 326
-SubTopic 20
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479344/326-20-45-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479837/606-10-45-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 326
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479319/326-20-50-13

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 326
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479319/326-20-50-13

+ Details

Name:	us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of write-down of royalty and commercial rights receivable recognized in the income statement during the period. Includes royalty purchase agreement asset impairment.

+ References

No definition available.

+ Details

Name:	xoma_ImpairmentOfLongTermRightsReceivableNonCurrent
Namespace Prefix:	xoma_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of milestone achieved.

+ References

No definition available.

+ Details

Name:	xoma_MilestoneAchieved
Namespace Prefix:	xoma_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Number of licensed products related to milestones and royalties purchased.

+ References

No definition available.

+ Details

Name:	xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased
Namespace Prefix:	xoma_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of cash outflow for consideration under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), Commercial payment purchase agreement (CPPAs) and other agreements classified as investing activities. Payments may include upfront payments, one-time payments, milestone payments and contingent consideration payments.

+ References

No definition available.

+ Details

Name:	xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities
Namespace Prefix:	xoma_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Purchased eligible milestone payments receivable upon achievement of potential development, regulatory and commercial milestones. May also include clinical milestones.

+ References

No definition available.

+ Details

Name:	xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones
Namespace Prefix:	xoma_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Percentage of milestones entity has the right to receive as a percentage.

+ References

No definition available.

+ Details

Name:	xoma_PurchasedPercentageOfMilestones
Namespace Prefix:	xoma_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Decrease in long-term rights receivable due to receipt of royalty and commercial payments.

+ References

No definition available.

+ Details

Name:	xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent
Namespace Prefix:	xoma_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Royalty and commercial payment receivables probable and reasonably estimable to be received within one year or the normal operating cycle, if longer.

+ References

No definition available.

+ Details

Name:	xoma_RightsReceivableCurrent
Namespace Prefix:	xoma_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Increase in long term rights receivable due acquisition of royalty, interest and commercial payment rights.

+ References

No definition available.

+ Details

Name:	xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent
Namespace Prefix:	xoma_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Royalties entity has the right to receive as a percentage of net sales.

+ References

No definition available.

+ Details

Name:	xoma_RoyaltyReceivablePercentageOnNetSales
Namespace Prefix:	xoma_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=xoma_MerckImmunoOncologyProductMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=xoma_AgenusIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=xoma_AgenusIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=xoma_IncyteImmunoOncologyAssetsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: